Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy.
In a randomised study of 558 children in an urban African community, the protective effect of the Edmonston-Zagreb (EZ) measles vaccine given in a dose of 40,000 plaque forming units from the age of 4 months was compared with the effects of a standard dose (6000 tissue culture infectious units) of Schwarz measles vaccine given from the age of 9 months. During two years of follow-up, all 14 clinical cases of measles occurred in the Schwarz group; 10 of the children contracted measles before vaccination and 4 after measles vaccination. Thus the EZ vaccine provided significant protection against measles both before and after the usual age of vaccination. Among the children who were exposed to measles at home, those given EZ vaccine were better protected than either unvaccinated children or those given the Schwarz vaccine.
D000367:Age Factors; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006169:Guinea-Bissau; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008457:Measles / Q000453:epidemiology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000627:therapeutic use; D011897:Random Allocation; D014505:Urban Population; D014611:Vaccination
D008458:Measles Vaccine